四環醫藥(00460.HK)注射用泮托拉唑鈉通過一致性評價
格隆匯1月26日丨四環醫藥(00460.HK)公佈,集團開發的注射用泮托拉唑鈉(40mg╱支)已獲得中國國家藥品監督管理局頒發的通過一致性評價藥品補充申請通知,取得第四批國家集中採購的申請資格;集團將有注射用泮托拉唑鈉、加巴噴丁膠囊及布洛芬注射液共三個品種參加此次國家集採。
注射用泮托拉唑鈉在國內上市較早,整體市場銷售額較大,在質子泵抑制劑市場佔有重要地位,屬於重磅品種。集團的注射用泮托拉唑鈉(40mg╱支)適用於十二指腸潰瘍、胃潰瘍、急性胃黏膜病變,複合性胃潰瘍等所致急性上消化道出血。集團已於2021年1月19日獲批通過一致性評價。
近幾年來中國醫院處方藥領域治療消化性潰瘍藥的市場規模逐年上漲,據2019年IQVIA數據顯示,質子泵抑制劑注射劑市場規模為人民幣154億元,而注射用泮托拉唑鈉是其中超人民幣40億元的重磅單品。
2021年1月15日,國家組織藥品集中採購和使用聯合採購辦公室發佈《全國藥品集中採購文件(GY-YD2021-1)》的公吿,第四批國家組織藥品集中採購和使用工作正式啟動。第四批國家集採開標時間為2021年2月3日,本批集採共45個品種、80個品規。隨着注射用泮托拉唑鈉順利拿到一致性過評批件,集團此次將有注射用泮托拉唑鈉、加巴噴丁膠囊及布洛芬注射液共三個品種參加此次國家集採。
集團研發的注射用泮托拉唑鈉通過一致性評價將有利於該藥品未來的市場銷售和市場競爭,如後續在第四批國家集採中順利中選,將進一步惠及廣大患者,同時將大大降低企業推廣成本並實現市場的快速覆蓋,對集團的經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.